Clinical Trials Logo

Clinical Trial Summary

This is a randomized, active-controlled, open-label study to assess the safety, tolerability and efficacy of Afabicin in the treatment of participants with bone or joint infection due to Staphylococcus aureus [both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)] and/or coagulase-negative staphylococci (CoNS) and to compare it to standard of care (SOC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03723551
Study type Interventional
Source Debiopharm International SA
Contact Debiopharm International S.A
Phone +41 21 321 01 11
Email clinicaltrials@debiopharm.com
Status Recruiting
Phase Phase 2
Start date February 20, 2019
Completion date March 31, 2026